摘要
结肠癌是常见的消化道恶性肿瘤。对术后患者以及无法采用手术治疗的患者,临床多采用化疗、放疗等综合性治疗方法。随着大量化疗药物在临床的广泛使用,结肠癌多药耐药性成为化疗失败的最主要原因。研究表明,P-糖蛋白(P-glycoprotein, P-gp)作为ATP结合盒(ABC)转运蛋白超家族成员之一,与多种肿瘤的多药耐药相关,其介导的多药耐药已经成为目前研究的热点。本文旨在通过对P-糖蛋白的结构、耐药机制以及逆转P-糖蛋白介导的结肠癌多药耐药新发现进行阐述,引导读者对P-糖蛋白在结肠癌多药耐药中的作用有更深入的了解。
Colon cancer is a common malignancy of the digestive tract. For postoperative patients and patients who can not be treated with surgical methods, comprehensive treatment methods such as chemotherapy and radiotherapy are used in the clinic. With the extensive use of chemotherapy drugs in the clinic, multidrug resistance of colon cancer has become the main cause of chemotherapy failure. Studies have shown that P-glycoprotein(P-gp), a member of the ATP binding cassette(ABC) transporter superfamily, is associated with multidrug resistance in a variety of tumors. Therefore the mechanism underlying its multi-drug resistance has become a hot spot of current research. The purpose of this paper is to provide a better understanding of the role of P-gp in multidrug resistance of colon cancer by introduces the structure of P-gp, drug resistance mechanism, and the new discovery of reverse P-gp-mediated multidrug resistance.
作者
丛熙
樊建慧
CONG Xi;FAN Jian-Hui(Department of Biochemistry and Molecular Biology,Dalian Medical University,Dalian 116044,Liaoning,China)
出处
《中国生物化学与分子生物学报》
CAS
CSCD
北大核心
2019年第1期19-26,共8页
Chinese Journal of Biochemistry and Molecular Biology
基金
国家自然科学基金项目(No.31400687)~~
关键词
P-糖蛋白
结肠癌
多药耐药
P-glycoprotein (P-gp)
colon cancer
multidrug resistance
作者简介
通讯作者:樊建慧,Tel:0411-86220312,E-mail:fanjh@dlmedu.edu.cn.
